Form 4: BDX Executive Michael Feld Reports Equity Transactions

Becton Dickinson & Co. EVP, CRO & Pres. Life Sciences, Michael Feld, reported the acquisition of restricted stock units and subsequent tax-related disposition.

Summary

• Michael Feld, EVP, CRO & Pres. Life Sciences at Becton Dickinson & Co. (BDX), reported transactions on November 26, 2025.
• He acquired 8,829 shares of Common Stock in the form of restricted stock units (RSUs) under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.
• Concurrently, 419 shares of Common Stock were disposed of to cover withholding taxes in connection with the vesting of previously reported restricted stock units.
• Following these reported transactions, Feld's direct beneficial ownership of Common Stock is 16,655 shares.

Sentiment

Score: 6

Explanation: The filing reports a routine executive equity award and associated tax withholding, which is a neutral event but indicates ongoing executive compensation and alignment.

Positives

• The grant of 8,829 restricted stock units aligns executive compensation with shareholder interests and incentivizes long-term performance.

Negatives

• The disposition of 419 shares for tax withholding reduces the executive's direct beneficial ownership, which is a standard but necessary reduction upon RSU vesting.

Future Outlook

NA

Industry Context

This filing details a routine insider transaction related to executive compensation, which is a common practice across various industries to align management incentives with company performance. It does not provide broader industry-specific insights or trends.

Stakeholder Impact

• Shareholders: The grant of restricted stock units aligns executive interests with shareholder value creation.
• Employees: Reflects standard executive compensation practices within the company.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the grant of restricted stock units and subsequent tax withholding. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transactions are standard practice for executive equity awards and do not signal any material positive or negative developments for Becton Dickinson & Co. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Becton Dickinson, BDX, Michael Feld, Form 4, Insider Transaction, Restricted Stock Units, Equity Compensation, Executive Compensation, Life Sciences